Who Paid My Doc
Elizabeth Malinowski
Registered Nurse Troy, MI Nurse Practitioner
NPI 1629703475 CMS profile 11374322
44201 Dequindre Rd, Troy, MI 48085
General payments
$467
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Elizabeth Malinowski of Troy, MI is reported in the CMS Open Payments database as having received $467 across 27 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 85th percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $210 | 10 | |
| 2023 | General | $257 | 17 |
Beside peers
- Elizabeth Malinowski
- Registered Nurse median
- Middle half of Registered Nurse
- National median
In program year 2025, general payments to Elizabeth Malinowski were reported at $0. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.
Show as a table
| Year | Elizabeth Malinowski | Registered Nurse median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $53 | $20–$148 | $132 |
| 2022 | $0 | $53 | $21–$146 | $149 |
| 2023 | $257 | $84 | $26–$196 | $160 |
| 2024 | $210 | $80 | $26–$187 | $164 |
| 2025 | $0 | $74 | $27–$193 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
666
Drug cost
$155,751
Branded share of claims
30.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 63 | $81,861 | |
| Xarelto Rivaroxaban | Brand | 47 | $50,977 | |
| Repatha Sureclick Evolocumab | Brand | 11 | $13,911 | |
| Metoprolol Succinate | Generic | 120 | $2,747 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 55 | $1,266 | |
| Atorvastatin Calcium | Generic | 68 | $1,135 | |
| Losartan Potassium | Generic | 55 | $741 | |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | Brand | 28 | $601 | |
| Amiodarone Hcl | Generic | 17 | $366 | |
| Ezetimibe | Generic | 18 | $360 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.
Records
27 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Registered Nurse in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.